vision: 177lu-psma-617 in psma-positive mcrpc
Published 2 years ago • 95 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
0:51
therap trial of 177lu-psma-617 review | david vanderweele, md | asco22 prostate cancer updates
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
6:01
asco daily news 2021 plenary update - lba4: vision
-
4:48
vision: lu-177-psma-617 in mcrpc
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
0:31
advancements in prostate cancer therapies from asco 2024
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
18:22
asco24 highlights: advances in nsclc
-
1:01:15
prostate cancer research updates: asco 2024 | zero prostate cancer
-
2:30
prostate cancer updates at asco 2021
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
0:33
asco 2024 highlights: the psmafore trial for patients with mcrpc
-
11:20
asco 2024: what's new in breast cancer research?
-
2:20
dr o'malley on updates in gynecologic oncology at the 2024 asco annual meeting
-
14:39
just the beginning: what's next for radiotheranostics in prostate cancer?
-
2:17
asco 2023: highlights in prostate cancer